Larvol Delta - Mateons-C001-A-Global-Phase-2-Study-For-OT101-Against-Covid19-Received-Clearance-For-Patient-Enrollment

trabedersen (OT-101) - Autotelic, Mateon Therapeutics

https://www.globenewswire.com/news-release/2020/11/04/2119989/0/en/MATEON-S-C001-A-GLOBAL-PHASE-2-STUDY-FOR-OT-101-AGAINST-COVID-19-RECEIVED-CLEARANCE-FOR-PATIENT-ENROLLMENT.html

Nov 4, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next